November 03, 2022

ValenzaBio Announces Positive Preliminary Data from Phase 1b/2a Trial of VB119, an Anti-CD19 Monoclonal Antibody for the Treatment of Primary Membranous Nephropathy

August 24, 2022

ValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors

March 31, 2022

ValenzaBio Announces FDA Clearance of Investigational New Drug Application for VB421, an Anti-IGF-1R Monoclonal Antibody for the Treatment of Thyroid Eye Disease

February 15, 2022

ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody

July 27, 2021

ValenzaBio Partners With ProBioGen to Maximize Cell Line Productivity and Licenses GlymaxX®

June 18, 2021

Lonza and ValenzaBio Enter Manufacturing Agreement to Rapidly Advance VB421, an Anti-IGF-1R Antibody for Autoimmune Diseases

May 27, 2021

ValenzaBio Appoints Biotech Veteran Gregory Keenan, M.D., as Chief Medical Officer

May 26, 2021

ValenzaBio Selects Ready by ArcheMedX to Expedite Biomarker Study

April 08, 2021

ValenzaBio Advances Pipeline of Antibody Therapeutics Toward Clinical Development for Autoimmune and Inflammatory Diseases